A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.

Trial Details

NCT ID
NCT06564272
Phase
PHASE2
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • KC1036
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age between 12 and less than 18 years;
  • Diagnosed with Ewing sarcoma confirmed by histopathological examination;
  • Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment o…
  • Body weight of ≥30 kg;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →